Advances in Targeting BCR-ABLT315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]
Tuzikiewicz A +3 more
europepmc +1 more source
Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms. [PDF]
Guo X +11 more
europepmc +1 more source
GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells. [PDF]
Wang JD +7 more
europepmc +1 more source
Correction to "Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML". [PDF]
Carolina P Lima M +3 more
europepmc +1 more source
[Allogeneic hematopoietic stem cell transplantation for the treatment of BCR::ABL-negative neutrophilic myeloid neoplasms: a clinical analysis of 12 cases]. [PDF]
Han TT +11 more
europepmc +1 more source
Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function. [PDF]
Zhang Y +12 more
europepmc +1 more source
T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy. [PDF]
Hsu MT +3 more
europepmc +1 more source

